+

US20110081407A1 - Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms - Google Patents

Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms Download PDF

Info

Publication number
US20110081407A1
US20110081407A1 US12/967,816 US96781610A US2011081407A1 US 20110081407 A1 US20110081407 A1 US 20110081407A1 US 96781610 A US96781610 A US 96781610A US 2011081407 A1 US2011081407 A1 US 2011081407A1
Authority
US
United States
Prior art keywords
antibody
ccl25
ccr9
fragment
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/967,816
Inventor
James W. Lillard
Shailesh Singh
Jonathan Stiles
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JYANT TECHNOLOGIES
Original Assignee
Morehouse School of Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morehouse School of Medicine Inc filed Critical Morehouse School of Medicine Inc
Priority to US12/967,816 priority Critical patent/US20110081407A1/en
Assigned to MOREHOUSE SCHOOL OF MEDICINE reassignment MOREHOUSE SCHOOL OF MEDICINE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LILLARD, JAMES W., SINGH, SHAILESH, STILES, JONATHAN K.
Publication of US20110081407A1 publication Critical patent/US20110081407A1/en
Assigned to STILES, JONATHAN K., SINGH, SHAILESH, LILLARD, JAMES W., JR reassignment STILES, JONATHAN K. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MOREHOUSE SCHOOL OF MEDICINE
Assigned to JYANT TECHNOLOGIES reassignment JYANT TECHNOLOGIES ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LILLARD, JAMES W., JR, SINGH, SHAILESH, STILES, JONATHAN K.
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Definitions

  • This invention relates to antibodies or the use of antibodies directed against certain chemokines.
  • the antibodies block high affinity interactions leading to the growth or migration of cancer cells.
  • Host cells have surface receptors that associate with ligands to signal and cause host cell activities.
  • the epidermal growth factor receptor helps control cell growth and metastasis.
  • Many tumor cells express higher numbers of epidermal growth factor receptors than normal cells.
  • a new treatment designated IMC-225 was specifically designed to target and block epidermal growth factor receptors preventing cell division and repair.
  • trastuzumab which is a HER-2-specific monoclonal antibody, has proven effective at treating metastatic breast cancers. This antibody blocks interactions on cancer cells that inhibit cell growth.
  • HER-2 is only found on about 25 to 30 percent of breast cancer cells.
  • Chemokines are a superfamily of small, cytokine-like proteins that are resistant to hydrolysis, promote neovascularization or endothelial cell growth inhibition, induce cytoskeletal rearrangement, activate or inactivate lymphocytes, and mediate chemotaxis through interactions with G-protein-coupled receptors. Chemokines can mediate the growth and migration of host cells that express their receptors. The cellular mechanisms responsible for the function of the chemokines are often, but not always, Ca 2+ flux dependent and pertussis toxin-sensitive. However, the precise mechanisms for chemokine-mediated events are not known
  • the present invention provides a means of inhibiting the growth and metastasis of cancer cells by administering anti-chemokine antibodies.
  • Exemplified are anti-CXCR1, -CXCR2, -CXCL1, -CXCL2, -CXCL3, -CXCL5, -CXCL6 -CXCL7, -CXCL8, -CXCL12, -CXCR5a, -CXCR5b, -CXCL13, -CXCR6, -CXCL16, -CCL16, -CCL25, -CCL25-1, -CCL25-2, -CX3CR1, and -CX3CL1 antibodies.
  • the invention relates to an antibody or functional fragment thereof that bind to CXCR1, CXCR2, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6 CXCL7, CXCL8, CXCL12, CXCR5a, CXCR5b, CXCL13, CXCR6, CXCL16, CCL16, CCL25, CCL25-1, CCL25-2, CX3CR1, and CX3CL1.
  • This invention utilizes antibodies or antigen-binding fragment(s) that bind to epitope(s) or peptide(s) that consists of 10 to 15 amino acids from Sequences 1 through 22.
  • the antibodies or antigen-binding fragement(s) can be isolated from the serum of immunized hosts, an immortalized cell lines or tissues such as hybridomas, lymphoblastoid or cells generated by methods of recombinant molecule biology.
  • antibodies and fragments may be conjugated or linked to other peptides, proteins, nucleic acid sequence, vitamins, complex or simple carbohydrates or other suitable carrier molecules.
  • Antibodies or antigen-binding fragments with specificity for functional mutant or variant mammalian chemokines are appropriate. These mutations or polymorphisms occur in nature or can be induced by recombinant molecular biological methods to generate single, multiple, or continuous amino acid residues, described in Sequences 1 through 22, that are deleted, added, and/or substituted for other or no amino acids.
  • Mucosal means include oral, intranasal, ocular, intravaginal, rectal and/or intraurethral administration in liquid or particulate form or on solid supports.
  • Systemic means include parenteral means such as intravenous, subcutaneous or intramuscular administration.
  • the invention describes a method of identifying and isolating cancer cells from adenoma, carcinoma, leukemia, lymphoma, melanoma, or myeloma using the antibodies in accord with the teachings of this specification.
  • anti-CXCR1, -CXCR2, -CXCL1, -CXCL2, -CXCL3, -CXCL5, -CXCL6 -CXCL7, -CXCL8,-CXCL12, -CXCR5a, -CXCR5b, -CXCL13, -CXCR6, -CXCL16, -CCL16, -CCL25, -CCL25-1, -CCL25-2, -CX3CR1, and -CX3CL1 antibodies can to administered to inhibit the rate of growth, metastasis and/or angiogenesis mediated by adenomas, carcinomas, leukemias, lymphomas, melanomas, and/or
  • RNA sequences for CXCR1, CXCR2, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6 CXCL7, CXCL8, CXCL12, CXCR5a, CXCR5b, CXCL13, CXCR6, CXCL16, CCL16,CCL25, CCL25-1, CCL25-2, CX3CR1, and CX3CL1 were obtained from the NIH-NCBI gene bank database (Sequences 23 through 44). Primers were designed using the BeaconJ 2.0 computer program. Thermodynamic analysis of the primers was conducted using computer programs: Primer PremierJ and MIT Primer 3. The resulting primer sets were compared against the entire human genome to confirm specificity.
  • RNA was then precipitated and resuspended in RNA Secure (Ambion, Austin, Tex.).
  • the cDNA was generated by reverse transcribing approximately 2 ⁇ g of total RNA using Taqman7 reverse transcription reagents (Applied-Biosystems, Foster City, Calif.) according to manufacturer's protocols.
  • cDNA's were amplified with specific human cDNA primers, to CXCR1, CXCR2, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6 CXCL7, CXCL8, CXCL12, CXCR5a, CXCR5b, CXCL13, CXCR6, CXCL16, CCL16, CCL25, CCL25-1, CCL25-2, CX3CR1, and CX3CL1, using SYBR7 Green PCR master mix reagents (Applied Biosystems) according to manufacturer's protocol. The level of copies of mRNA of these targets were evaluated by real-time PCR analysis using the BioRad Icycler and software (Hercules, Calif.).
  • the 15 amino acid peptides from CXCR1, CXCR2, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6 CXCL7, CXCL8, CXCL12, CXCR5a, CXCR5b, CXCL13, CXCR6, CXCL16, CCL16, CCL25, CCL25-1, CCL25-2, CX3CR1, and CX3CL1 were synthesized (Sigma Genosys, The Woodlands, Tex.) and conjugated to hen egg lysozyme (Pierce, Rockford, Ill.) to generate the “antigen” for subsequent immunizations for anti-sera preparation or monoclonal antibody generation.
  • chemokine peptide conjugates were quantified by the chromogenic Limulus amebocyte lysate assay (Cape Cod, Inc., Falmouth, Mass.) and shown to be ⁇ 5 EU/mg. 100 ⁇ g of the antigen was used as the immunogen together with complete Freund's adjuvant Ribi Adjuvant system (RAS) for the first immunization in a final volume of 1.0 ml. This mixture was administered in 100 ml aliquots on two sites of the back of the rabbit subcutaneously and 400 ml intramuscularly in each hind leg muscle.
  • Ribi Adjuvant system Ribi Adjuvant system
  • rabbits received 100 ⁇ g of the antigen in addition to incomplete Freund's adjuvant for 3 subsequent immunizations.
  • Anti-sera were collected when anti-CXCR1, -CXCR2, -CXCL1, -CXCL2, -CXCL3, -CXCL5, -CXCL6 -CXCL7, -CXCL8, -CXCL12, -CXCR5a, -CXCR5b, -CXCL13, -CXCR6, -CXCL16, -CCL16, -CCL25, -CCL25-1, -CCL25-2, -CX3CR1, and -CX3CL1 antibody titers reached 1:1,000,000. Subsequently, normal or anti-sera were heat-inactivated and diluted 1:50 in PBS.
  • the 15 amino acid peptides from CXCR1, CXCR2, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6 CXCL7, CXCL8, CXCL12, CXCR5a, CXCR5b, CXCL13, CXCR6, CXCL16, CCL16, CCL25, CCL25-1, CCL25-2, CX3CR1, and CX3CL1 were synthesized (Sigma Genosys) and conjugated to hen egg lysozyme (Pierce) to generate the “antigen” for subsequent immunizations for anti-sera preparation or monoclonal antibody generation.
  • chemokine peptide conjugates were quantified by the chromogenic Limulus amebocyte lysate assay (Cape Cod, Inc., Falmouth, Mass.) and shown to be ⁇ 5 EU/mg.
  • 100 ⁇ g of the antigen was used as the immunogen together with complete Freund's adjuvant Ribi Adjuvant system (RAS) for the first immunization in a final volume of 200 ⁇ l.
  • RRS complete Freund's adjuvant Ribi Adjuvant system
  • This mixture was subcutaneously administered in 100 ⁇ l aliquots at two sites of the back of a rat, mouse, or immunoglobulin-humanized mouse. Two weeks later, animals received 100 ⁇ g of the antigen in addition to incomplete Freund's adjuvant for 3 subsequent immunizations.
  • Serum were collected and when anti-CXCR1, -CXCR2, -CXCL1, -CXCL2, -CXCL3, -CXCL5, -CXCL6 -CXCL7, -CXCL8, -CXCL12, -CXCR5a, -CXCR5b, -CXCL13, -CXCR6, -CXCL16, -CCL16, -CCL25, -CCL25-1, -CCL25-2, -CX3CR1, or -CX3CL1 antibody titers reached 1:2,000,000, hosts were sacrificed and splenocytes were isolated for hybridoma generation.
  • Hybridomas were next isolated after selective culturing conditions (i.e., HAT-supplemented media) and limiting dilution methods of hybridoma cloning. Cells that produce antibodies with the desired specificity were selected using ELISA. Hybridomas from normal rats or mice were humanized with molecular biological techniques in common use. After cloning a high affinity and prolific hybridoma, antibodies were isolated from ascites or culture supernatants and adjusted to a titer of 1:2,000,000 and diluted 1:50 in PBS.
  • the NIH-III mice (8 to 12 weeks old, Charles River Laboratory, Wilmington, Mass.), which lack T, B, and NK cells, received 1 ⁇ 10 6 cancer cells, subcutaneously, for the establishment of a tumor.
  • freshly isolated or liquid nitrogen frozen 1 g of tumor tissue were surgically implanted in the intestinal adipose tissue for the generation of tumor.
  • the NIH-III mice received 200.mu.l intraperitoneal injections of either antisera or monoclonal antibodies every three days and the tumor was monitored for progression or regression of growth.
  • SigmaStat 2000 (Chicago, Ill.) software was used to analyze and confirm the statistical significance of data. The data were subsequently analyzed by the Student's t-test, using a two-factor, unpaired test. In this analysis, treated samples were compared to untreated controls. The significance level was set at p ⁇ 0.05.
  • RT-PCR products obtained using CXCR1-, CXCR2-, CXCL1-, CXCL2-, CXCL3-, CXCL5-, CXCL6-, CXCL7-, CXCL8-, CXCL12-, CXCR5a-, CXCR5b-, CXCL13-, CXCR6-, CXCL16-, CCL16-, CCL25-, CCL25-1-, CCL25-2-, CX3CR1-, or CX3CL1-specific primer sets did not cross react with other gene targets due to exclusion of primers that annealed to host sequences (NIH-NCBI Genebank).
  • the primers used produced different size amplicon products relative the polymorphisms that resulted in CXCR5a versus CXCR5b and CCL25, CCL25-1, versus CCL25-2.
  • RT-PCR analysis of adenoma, carcinoma, leukemia, lymphoma, melanoma, and/or myeloma cell lines and tumor tissue revealed that CXCR1, CXCR2, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6 CXCL7, CXCL8, CXCR4, CXCL12, CXCR5a, CXCR5b, CXCL13, CXCR6, CXCL16, CCL16, CCR9, CCL25, CCL25-1, CCL25-2, CX3CR1, and CX3CL1 were differentially expressed by cancer cells.
  • the adenoma, carcinoma, leukemia, lymphoma, melanoma, and/or myeloma cell lines were grown in complete media in the presence or absence of antibodies specific for CXCR1, CXCR2, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6 CXCL7, CXCL8, CXCR4, CXCL12, CXCR5a, CXCR5b, CXCL13, CXCR6, CXCL16, CCL16, CCR9, CCL25, CCL25-1, CCL25-2, CX3CR1, or CX3CL1.
  • cancer cell lines expressing CXCR1 and/or CXCR2 were inhibited by antibodies to CXCR1, CXCR2, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6 CXCL7, or CXCL8.
  • the growth of cancer cell lines expressing CXCR4 were inhibited by antibodies to CXCR4 or CXCL12.
  • the growth of cancer cell lines expressing CXCR5a or CXCR5a were inhibited by antibodies to CXCR5a, CXCR5b, or CXCL13.
  • cancer cell lines expressing CCR9 were inhibited by antibodies to CCR9 or CCL25, CCL25-1, and CCL25-2.
  • the propagation of cancer cell lines expressing CX3CR1 were inhibited by antibodies to CX3CR1 or CXC3L1.
  • antibodies against the soluble ligands, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, CXCL8, CXCL12, CXCL13, CXCL16, CCL16, CCL25, CCL25-1, CCL25-2, or CX3CL1 were more effective at growth inhibition that those directed against the membrane receptors.
  • microvascular endothelial cells (Cell Systems, Wirkland, Wash.) were grown according to manufacturer's protocols and allowed to form microvascular venules in an in vitro assay for angiogenesis (BD-Biocoat, Hercules, in the presence or absence of antibodies specific for CXCR1, CXCR2, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6 CXCL7, CXCL8, CXCR4, CXCL12, CXCR5a, CXCR5b, CXCL13, CXCR6, CXCL16, CCL16, CCR9, CCL25, CCL25-1, CCL25-2, CX3CR1, or CX3CL1.
  • the angiogenesis was inhibited by antibodies against CXCR1, CXCR2, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6 CXCL7, CXCL8, CXCR4, CXCL12, CXCR6 or CXCL16.
  • Cancer cell lines or primary tumor tissue were adoptively transferred into NIH-III mice and allowed to form the xenograft tumor of interest.
  • Antibodies directed against CXCR1, CXCR2, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6 CXCL7, CXCL8, CXCR4, CXCL12, CXCR5a, CXCR5b, CXCL13, CXCR6, CXCL16, CCL16, CCR9, CCL25, CCL25-1, CCL25-2; CX3CR1, or CX3CL1 differentially affected the progression and regression of tumor size.
  • antibodies directed towards CXCR1, CXCR2, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6 CXCL7, CXCL8, CXCR4, CXCL12, CXCR6 or CXCL16 effectively lead to the both regression and impeding progression of tumor growth.
  • Antibodies directed against CXCR4, CXCL12, CXCR5a, CXCR5b, CXCL13, CCL16, CCR9, CCL25, CCL25-1, CCL25-2, CX3CR1, or CX3CL1 were effective at inhibiting the progression of tumor size.
  • the protein sequences of the chemokines used herein are recorded in NIH-NCBI Genebank as: (1) CXCR1 (ACCESSION# NM 000634), (2) CXCR2(ACCESSION# NM 001557), (3) CXCL1 (ACCESSION# NM — 001511), (4) CXCL2 (ACCESSION# NM — 001557), (5) CXCL3 (ACCESSION# NM — 002090), (6) CXCL5 (ACCESSION# NM — 002994), (7) CXCL6 (ACCESSION# NM — 002993), (8) CXCL7 (ACCESSION# NM — 002704), (9) CXCL8 (ACCESSION# XM — 170504), (10) CXCR4 (ACCESSION# NM — 003467), (11) CXCL12 (ACCESSION# NM — 000609), (12) CXCR5A (ACCESSION# NM — 03
  • the cDNA sequences are known and are available in NIH-NCBI Genebank under the following accession numbers: (23) CXCR1 (ACCESSION# NM 000634), (24) CXCR2 (ACCESSION# NM 001557), (25) CXCL1 (ACCESSION# NM — 01511).
  • the particular chemokines which are most which any tumor expresses may vary. It is possible, using methods of the invention, to customize treatment for the particular patient, depending on the chemokines over-expressed by the patient's own tumor. It is possible to identify the particular chemokines which are over-expressed in the tumor using methods of the invention and administer antibodies against that over-expressed chemokine.
  • the tailoring of treatment for the cancer patient is novel, and is a particularly valuable aspect of the invention.
  • the method consists of 1) exposing samples of malignant tissue or products therefrom to an array of antibodies to different chemokines, allowing the antibodies to bind to the malignant tissue, then measure the amount of the chemokines by measuring the amount of chemokine bound to particular antibodies to identify the level of expression of each chemokine. The patient is then given the antibodies against the over-expressed chemokine(s). However, the level of each chemokine may also be evaluated using PCR technologies. Such direct evaluation is now easily done, as shown above. See particularly the section entitled, “Semiquantitative RT-PCR identification of molecular targets”.
  • Antibodies of the invention can be administered in the usually accepted pharmaceutically acceptable carriers.
  • compositions containing antibodies can be prepared in accord with the section entitled “Monoclonal antibody preparation”.
  • Acceptable carriers include, but are not limited to, saline, buffered saline, glucose in saline. Solid supports, liposomes or microspheres may also be used as carriers for administration of the antibodies.
  • Antibodies of the invention may be administered directly to target tissue.
  • compositions containing the compositions containing antibodies as prepared under the heading “anti-sera preparation” can be administered intravenously, rectally vaginally, intrathecally, by inhalation, transvaginally, transurethrally or directly to tissue during surgery.
  • the anti-sera preparations may also be placed on a solid support such as a sponge or gauze for administration of antibodies against the target chemokine to the affected tissues, including administration directly to the tumor bed during invasive procedures.
  • a solid support such as a sponge or gauze
  • administration of antibodies against the target chemokine to the affected tissues including administration directly to the tumor bed during invasive procedures.
  • the table on the following page indicates the differing amounts of particular chemokines over-expressed in particular tumors that were studied.
  • Chemokine Receptor Carci- CCL1, CCL4, CCL17, CCL19, CCL21, CCR7, CCR8, noma CCL22, CCL25 CCR9 CXCL12, CXCL13, CXCL16 CXCR4, CXCR5, CXCR6, CX3CR1 Leuke- CCL1, CCL4, CCL17, CCL19, CCL21, CCR7, CCR8, mia CCL22, CCL25 CCR9 CXCL12 CXCR4 Lym- CXCL12, CXCL13 CXCR4, CXCR5 phoma Mela- CCL25, CCL27 CCR9, CCR10 noma CXCL1, CXCL2, CXCL3, CXCL5, CXCR1, CXCR2, CXCL6, CXCL7, CXCL8, CXCL12, CXCR4, CXCR5, CXCL13
  • Dosage would more commonly be in the range of 0.01 to 1000 mg/kg/da, more often in the range of 0.1 to 100 mg/kg/da. As expected, the dosage will be dependant on the condition, size, age and condition of the patient.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a means of inhibiting the growth and metastasis of cancer cells by administering anti-chemokine antibodies. It is possible to identify the particular chemokines which are over-expressed in the tumor using methods of the invention and administer antibodies against that over-expressed chemokine.

Description

  • This application is a continuation application of U.S. patent application Ser. No. 10/712,398, filed on Nov. 14, 2003, which claims priority from U.S. Provisional Patent Application 60/426,347, filed on Nov. 15, 2002. The entirety of all of the aforementioned applications is incorporated herein by reference.
  • This work was partially supported by the United States government, which has certain rights in the invention.
    • FIELD
  • This invention relates to antibodies or the use of antibodies directed against certain chemokines. The antibodies block high affinity interactions leading to the growth or migration of cancer cells.
    • BACKGROUND
  • Despite recent advances in cancer research, the development of cell-specific therapies for treatment of malignancies remain elusive. The many and complex factors which enable malignant cells to undergo mutations, evade immune protection and promote angiogenesis to deliver nutrients to the rapidly growing cells complicate the development of targeted treatment modalities. Current therapies have multiple untoward side effects. For example, chemotherapy results in multiple painful and sometimes lethal side effects. Advances in biotechnology have promoted the development of targeted biologicals with fewer side effects.
  • Host cells have surface receptors that associate with ligands to signal and cause host cell activities. The epidermal growth factor receptor helps control cell growth and metastasis. Many tumor cells express higher numbers of epidermal growth factor receptors than normal cells. A new treatment designated IMC-225 was specifically designed to target and block epidermal growth factor receptors preventing cell division and repair. Recently, trastuzumab, which is a HER-2-specific monoclonal antibody, has proven effective at treating metastatic breast cancers. This antibody blocks interactions on cancer cells that inhibit cell growth. Unfortunately, HER-2 is only found on about 25 to 30 percent of breast cancer cells.
  • A variety of pathogens or toxins activate macrophages, neutrophils, T cells, B cells, monocytes, NK cells, Paneth and crypt cells, as well as epithelial cells shortly after entry into the mucosa. Chemokines are a superfamily of small, cytokine-like proteins that are resistant to hydrolysis, promote neovascularization or endothelial cell growth inhibition, induce cytoskeletal rearrangement, activate or inactivate lymphocytes, and mediate chemotaxis through interactions with G-protein-coupled receptors. Chemokines can mediate the growth and migration of host cells that express their receptors. The cellular mechanisms responsible for the function of the chemokines are often, but not always, Ca2+ flux dependent and pertussis toxin-sensitive. However, the precise mechanisms for chemokine-mediated events are not known
    • SUMMARY
  • The present invention provides a means of inhibiting the growth and metastasis of cancer cells by administering anti-chemokine antibodies. Exemplified are anti-CXCR1, -CXCR2, -CXCL1, -CXCL2, -CXCL3, -CXCL5, -CXCL6 -CXCL7, -CXCL8, -CXCL12, -CXCR5a, -CXCR5b, -CXCL13, -CXCR6, -CXCL16, -CCL16, -CCL25, -CCL25-1, -CCL25-2, -CX3CR1, and -CX3CL1 antibodies. The invention relates to an antibody or functional fragment thereof that bind to CXCR1, CXCR2, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6 CXCL7, CXCL8, CXCL12, CXCR5a, CXCR5b, CXCL13, CXCR6, CXCL16, CCL16, CCL25, CCL25-1, CCL25-2, CX3CR1, and CX3CL1. This invention utilizes antibodies or antigen-binding fragment(s) that bind to epitope(s) or peptide(s) that consists of 10 to 15 amino acids from Sequences 1 through 22. The antibodies or antigen-binding fragement(s) can be isolated from the serum of immunized hosts, an immortalized cell lines or tissues such as hybridomas, lymphoblastoid or cells generated by methods of recombinant molecule biology. For increased effectiveness, antibodies and fragments may be conjugated or linked to other peptides, proteins, nucleic acid sequence, vitamins, complex or simple carbohydrates or other suitable carrier molecules.
  • Antibodies or antigen-binding fragments with specificity for functional mutant or variant mammalian chemokines are appropriate. These mutations or polymorphisms occur in nature or can be induced by recombinant molecular biological methods to generate single, multiple, or continuous amino acid residues, described in Sequences 1 through 22, that are deleted, added, and/or substituted for other or no amino acids.
  • The antibodies for use in accord with the teachings of this specification may be administered systemically or mucosally. Mucosal means include oral, intranasal, ocular, intravaginal, rectal and/or intraurethral administration in liquid or particulate form or on solid supports. Systemic means include parenteral means such as intravenous, subcutaneous or intramuscular administration.
    • DETAILED DESCRIPTION
  • The invention describes a method of identifying and isolating cancer cells from adenoma, carcinoma, leukemia, lymphoma, melanoma, or myeloma using the antibodies in accord with the teachings of this specification. Also, as demonstrated herein, anti-CXCR1, -CXCR2, -CXCL1, -CXCL2, -CXCL3, -CXCL5, -CXCL6 -CXCL7, -CXCL8,-CXCL12, -CXCR5a, -CXCR5b, -CXCL13, -CXCR6, -CXCL16, -CCL16, -CCL25, -CCL25-1, -CCL25-2, -CX3CR1, and -CX3CL1 antibodies can to administered to inhibit the rate of growth, metastasis and/or angiogenesis mediated by adenomas, carcinomas, leukemias, lymphomas, melanomas, and/or myelomas.
    • Materials and Methods Primer Design
  • Messenger RNA sequences for CXCR1, CXCR2, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6 CXCL7, CXCL8, CXCL12, CXCR5a, CXCR5b, CXCL13, CXCR6, CXCL16, CCL16,CCL25, CCL25-1, CCL25-2, CX3CR1, and CX3CL1 were obtained from the NIH-NCBI gene bank database (Sequences 23 through 44). Primers were designed using the BeaconJ 2.0 computer program. Thermodynamic analysis of the primers was conducted using computer programs: Primer PremierJ and MIT Primer 3. The resulting primer sets were compared against the entire human genome to confirm specificity.
    • Real Time PCR Analysis
  • Cancer cell lines (ATCC, Rockville, Md.) were cultured in RMPI-1640 containing 10% fetal calf serum supplemented with non-essential amino acids, L-glutamate, and sodium pyruvate (complete media). Primary tumor and normal-paired matched tissues were obtained from clinical isolates (Clinomics Biosciences, Frederick, Md. and UAB Tissue Procurement, Birmingham, Ala.). Messenger RNA (mRNA) was isolated from 106 cells using TriReagent (Molecular Research Center, Cincinnati, Ohio) according to manufacturer's protocols. Potential genomic DNA contamination was removed from these samples by treatment with 10 U/Fl of RNase free DNase (Invitrogen, San Diego, Calif.) for 15 minutes at 37° C. RNA was then precipitated and resuspended in RNA Secure (Ambion, Austin, Tex.). The cDNA was generated by reverse transcribing approximately 2 μg of total RNA using Taqman7 reverse transcription reagents (Applied-Biosystems, Foster City, Calif.) according to manufacturer's protocols. Subsequently, cDNA's were amplified with specific human cDNA primers, to CXCR1, CXCR2, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6 CXCL7, CXCL8, CXCL12, CXCR5a, CXCR5b, CXCL13, CXCR6, CXCL16, CCL16, CCL25, CCL25-1, CCL25-2, CX3CR1, and CX3CL1, using SYBR7 Green PCR master mix reagents (Applied Biosystems) according to manufacturer's protocol. The level of copies of mRNA of these targets were evaluated by real-time PCR analysis using the BioRad Icycler and software (Hercules, Calif.).
    • Anti-Sera Preparation
  • The 15 amino acid peptides from CXCR1, CXCR2, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6 CXCL7, CXCL8, CXCL12, CXCR5a, CXCR5b, CXCL13, CXCR6, CXCL16, CCL16, CCL25, CCL25-1, CCL25-2, CX3CR1, and CX3CL1 (Sequences 1 through 22) were synthesized (Sigma Genosys, The Woodlands, Tex.) and conjugated to hen egg lysozyme (Pierce, Rockford, Ill.) to generate the “antigen” for subsequent immunizations for anti-sera preparation or monoclonal antibody generation. The endotoxin levels of chemokine peptide conjugates were quantified by the chromogenic Limulus amebocyte lysate assay (Cape Cod, Inc., Falmouth, Mass.) and shown to be <5 EU/mg. 100 μg of the antigen was used as the immunogen together with complete Freund's adjuvant Ribi Adjuvant system (RAS) for the first immunization in a final volume of 1.0 ml. This mixture was administered in 100 ml aliquots on two sites of the back of the rabbit subcutaneously and 400 ml intramuscularly in each hind leg muscle. Three to four weeks later, rabbits received 100 μg of the antigen in addition to incomplete Freund's adjuvant for 3 subsequent immunizations. Anti-sera were collected when anti-CXCR1, -CXCR2, -CXCL1, -CXCL2, -CXCL3, -CXCL5, -CXCL6 -CXCL7, -CXCL8, -CXCL12, -CXCR5a, -CXCR5b, -CXCL13, -CXCR6, -CXCL16, -CCL16, -CCL25, -CCL25-1, -CCL25-2, -CX3CR1, and -CX3CL1 antibody titers reached 1:1,000,000. Subsequently, normal or anti-sera were heat-inactivated and diluted 1:50 in PBS.
    • Monoclonal Antibody Preparation
  • The 15 amino acid peptides from CXCR1, CXCR2, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6 CXCL7, CXCL8, CXCL12, CXCR5a, CXCR5b, CXCL13, CXCR6, CXCL16, CCL16, CCL25, CCL25-1, CCL25-2, CX3CR1, and CX3CL1 (Sequences 1 through 22) were synthesized (Sigma Genosys) and conjugated to hen egg lysozyme (Pierce) to generate the “antigen” for subsequent immunizations for anti-sera preparation or monoclonal antibody generation. The endotoxin levels of chemokine peptide conjugates were quantified by the chromogenic Limulus amebocyte lysate assay (Cape Cod, Inc., Falmouth, Mass.) and shown to be <5 EU/mg. 100 μg of the antigen was used as the immunogen together with complete Freund's adjuvant Ribi Adjuvant system (RAS) for the first immunization in a final volume of 200 μl. This mixture was subcutaneously administered in 100 μl aliquots at two sites of the back of a rat, mouse, or immunoglobulin-humanized mouse. Two weeks later, animals received 100 μg of the antigen in addition to incomplete Freund's adjuvant for 3 subsequent immunizations. Serum were collected and when anti-CXCR1, -CXCR2, -CXCL1, -CXCL2, -CXCL3, -CXCL5, -CXCL6 -CXCL7, -CXCL8, -CXCL12, -CXCR5a, -CXCR5b, -CXCL13, -CXCR6, -CXCL16, -CCL16, -CCL25, -CCL25-1, -CCL25-2, -CX3CR1, or -CX3CL1 antibody titers reached 1:2,000,000, hosts were sacrificed and splenocytes were isolated for hybridoma generation. Briefly, B cells from the spleen or lymph nodes of immunized hosts were fused with immortal myeloma cell lines (e.g., YB2/0). Hybridomas were next isolated after selective culturing conditions (i.e., HAT-supplemented media) and limiting dilution methods of hybridoma cloning. Cells that produce antibodies with the desired specificity were selected using ELISA. Hybridomas from normal rats or mice were humanized with molecular biological techniques in common use. After cloning a high affinity and prolific hybridoma, antibodies were isolated from ascites or culture supernatants and adjusted to a titer of 1:2,000,000 and diluted 1:50 in PBS.
    • Anti-Sera or Monoclonal Antibody Treatment
  • The NIH-III mice (8 to 12 weeks old, Charles River Laboratory, Wilmington, Mass.), which lack T, B, and NK cells, received 1×106 cancer cells, subcutaneously, for the establishment of a tumor. Correspondingly, freshly isolated or liquid nitrogen frozen 1 g of tumor tissue were surgically implanted in the intestinal adipose tissue for the generation of tumor. Once the xenografted tumor growth reached 5 mm in size the NIH-III mice received 200.mu.l intraperitoneal injections of either antisera or monoclonal antibodies every three days and the tumor was monitored for progression or regression of growth.
    • Data Analysis
  • SigmaStat 2000 (Chicago, Ill.) software was used to analyze and confirm the statistical significance of data. The data were subsequently analyzed by the Student's t-test, using a two-factor, unpaired test. In this analysis, treated samples were compared to untreated controls. The significance level was set at p<0.05.
    • Results
  • Semiquantitative RT-PCR Identification of Molecular Targets
  • The RT-PCR products obtained using CXCR1-, CXCR2-, CXCL1-, CXCL2-, CXCL3-, CXCL5-, CXCL6-, CXCL7-, CXCL8-, CXCL12-, CXCR5a-, CXCR5b-, CXCL13-, CXCR6-, CXCL16-, CCL16-, CCL25-, CCL25-1-, CCL25-2-, CX3CR1-, or CX3CL1-specific primer sets did not cross react with other gene targets due to exclusion of primers that annealed to host sequences (NIH-NCBI Genebank). The primers used produced different size amplicon products relative the polymorphisms that resulted in CXCR5a versus CXCR5b and CCL25, CCL25-1, versus CCL25-2. To this end, RT-PCR analysis of adenoma, carcinoma, leukemia, lymphoma, melanoma, and/or myeloma cell lines and tumor tissue revealed that CXCR1, CXCR2, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6 CXCL7, CXCL8, CXCR4, CXCL12, CXCR5a, CXCR5b, CXCL13, CXCR6, CXCL16, CCL16, CCR9, CCL25, CCL25-1, CCL25-2, CX3CR1, and CX3CL1 were differentially expressed by cancer cells.
  • In vitro Growth Studies
  • The adenoma, carcinoma, leukemia, lymphoma, melanoma, and/or myeloma cell lines were grown in complete media in the presence or absence of antibodies specific for CXCR1, CXCR2, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6 CXCL7, CXCL8, CXCR4, CXCL12, CXCR5a, CXCR5b, CXCL13, CXCR6, CXCL16, CCL16, CCR9, CCL25, CCL25-1, CCL25-2, CX3CR1, or CX3CL1. The growth of cancer cell lines expressing CXCR1 and/or CXCR2 were inhibited by antibodies to CXCR1, CXCR2, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6 CXCL7, or CXCL8. Similarly, the growth of cancer cell lines expressing CXCR4 were inhibited by antibodies to CXCR4 or CXCL12. The growth of cancer cell lines expressing CXCR5a or CXCR5a were inhibited by antibodies to CXCR5a, CXCR5b, or CXCL13. The proliferation of cancer cell lines expressing CXCR6 or were inhibited by antibodies to CXCR6 or CXCL16. The growth of cancer cell lines expressing CCR9 were inhibited by antibodies to CCR9 or CCL25, CCL25-1, and CCL25-2. The propagation of cancer cell lines expressing CX3CR1 were inhibited by antibodies to CX3CR1 or CXC3L1. Of interest, antibodies against the soluble ligands, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, CXCL8, CXCL12, CXCL13, CXCL16, CCL16, CCL25, CCL25-1, CCL25-2, or CX3CL1, were more effective at growth inhibition that those directed against the membrane receptors.
  • In vitro Angiogenesis Studies
  • The microvascular endothelial cells (Cell Systems, Wirkland, Wash.) were grown according to manufacturer's protocols and allowed to form microvascular venules in an in vitro assay for angiogenesis (BD-Biocoat, Hercules, in the presence or absence of antibodies specific for CXCR1, CXCR2, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6 CXCL7, CXCL8, CXCR4, CXCL12, CXCR5a, CXCR5b, CXCL13, CXCR6, CXCL16, CCL16, CCR9, CCL25, CCL25-1, CCL25-2, CX3CR1, or CX3CL1. The angiogenesis was inhibited by antibodies against CXCR1, CXCR2, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6 CXCL7, CXCL8, CXCR4, CXCL12, CXCR6 or CXCL16.
  • In vivo Growth Studies
  • Cancer cell lines or primary tumor tissue were adoptively transferred into NIH-III mice and allowed to form the xenograft tumor of interest. Antibodies directed against CXCR1, CXCR2, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6 CXCL7, CXCL8, CXCR4, CXCL12, CXCR5a, CXCR5b, CXCL13, CXCR6, CXCL16, CCL16, CCR9, CCL25, CCL25-1, CCL25-2; CX3CR1, or CX3CL1 differentially affected the progression and regression of tumor size. In certain cases, antibodies directed towards CXCR1, CXCR2, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6 CXCL7, CXCL8, CXCR4, CXCL12, CXCR6 or CXCL16 effectively lead to the both regression and impeding progression of tumor growth. Antibodies directed against CXCR4, CXCL12, CXCR5a, CXCR5b, CXCL13, CCL16, CCR9, CCL25, CCL25-1, CCL25-2, CX3CR1, or CX3CL1 were effective at inhibiting the progression of tumor size.
  • The protein sequences of the chemokines used herein are recorded in NIH-NCBI Genebank as: (1) CXCR1 (ACCESSION# NM 000634), (2) CXCR2(ACCESSION# NM 001557), (3) CXCL1 (ACCESSION# NM—001511), (4) CXCL2 (ACCESSION# NM—001557), (5) CXCL3 (ACCESSION# NM—002090), (6) CXCL5 (ACCESSION# NM—002994), (7) CXCL6 (ACCESSION# NM—002993), (8) CXCL7 (ACCESSION# NM—002704), (9) CXCL8 (ACCESSION# XM—170504), (10) CXCR4 (ACCESSION# NM—003467), (11) CXCL12 (ACCESSION# NM—000609), (12) CXCR5A (ACCESSION# NM—032966), (13) CXCR5B (ACCESSION# NM—001716), (14) CXCL13 (ACCESSION# NM—006419), (15) CXCR6 (ACCESSION# NM—006564), (16) CXCL16 (ACCESSION# NM022059), (17) CCL16 (ACCESSION# NM—004590), (18) CCL25 (ACCESSION#015444), (19) CCL25-1 (ACCESSION# NM—005624), (20) CCL25-2 (ACCESSION# NM—148888), (21) CX3CR1 (ACCESSION# NM—001337), and (22) CX3CL1 (ACCESSION# NM—002996).
  • The cDNA sequences are known and are available in NIH-NCBI Genebank under the following accession numbers: (23) CXCR1 (ACCESSION# NM 000634), (24) CXCR2 (ACCESSION# NM 001557), (25) CXCL1 (ACCESSION# NM—01511). (26) CXCL2 (ACCESSION# NM—001557), (27) CXCL3 (ACCESSION# NM—002090), (28) CXCL5 (ACCESSION# NM—002994), (29) CXCL6 (ACCESSION# NM—002993), (30) CXCL7 (ACCESSION# NM—002704), (31) CXCL8 (ACCESSION# XM—170504), (32) CXCR4 (ACCESSION# NM—003467), (33) CXCL12 (ACCESSION# NM—000609), (34) CXCR5A (ACCESSION# NM—032966), (35) CXCRSB (ACCESSION# NM—001716) (36) CXCL13 (ACCESSION# NM—006419), (37) CXCR6 (ACCESSION# NM—006564), (38) CXCL16 (ACCESSION# NM—022059), (39) CCL16 (ACCESSION# NM—004590), (40) CCL25 (ACCESSION#015444), (41) CCL25-1 (ACCESSION# NM—005624), (42) CCL25-2 (ACCESSION# NM—148888), (43) CX3CR1 (ACCESSION# NM—001337), and (44) CX3CL1 (ACCESSION# NM—002996).
  • As shown in the table below, the particular chemokines which are most which any tumor expresses may vary. It is possible, using methods of the invention, to customize treatment for the particular patient, depending on the chemokines over-expressed by the patient's own tumor. It is possible to identify the particular chemokines which are over-expressed in the tumor using methods of the invention and administer antibodies against that over-expressed chemokine. The tailoring of treatment for the cancer patient is novel, and is a particularly valuable aspect of the invention.
  • The method consists of 1) exposing samples of malignant tissue or products therefrom to an array of antibodies to different chemokines, allowing the antibodies to bind to the malignant tissue, then measure the amount of the chemokines by measuring the amount of chemokine bound to particular antibodies to identify the level of expression of each chemokine. The patient is then given the antibodies against the over-expressed chemokine(s). However, the level of each chemokine may also be evaluated using PCR technologies. Such direct evaluation is now easily done, as shown above. See particularly the section entitled, “Semiquantitative RT-PCR identification of molecular targets”.
  • Antibodies of the invention can be administered in the usually accepted pharmaceutically acceptable carriers. For example, compositions containing antibodies can be prepared in accord with the section entitled “Monoclonal antibody preparation”. Acceptable carriers include, but are not limited to, saline, buffered saline, glucose in saline. Solid supports, liposomes or microspheres may also be used as carriers for administration of the antibodies. Antibodies of the invention may be administered directly to target tissue. For example, compositions containing the compositions containing antibodies as prepared under the heading “anti-sera preparation” can be administered intravenously, rectally vaginally, intrathecally, by inhalation, transvaginally, transurethrally or directly to tissue during surgery. The anti-sera preparations may also be placed on a solid support such as a sponge or gauze for administration of antibodies against the target chemokine to the affected tissues, including administration directly to the tumor bed during invasive procedures. The table on the following page indicates the differing amounts of particular chemokines over-expressed in particular tumors that were studied.
  • TABLE I
    Chemokine, Chemokine Receptor and Cancer Association
    (dependent of stage of disease)
    Cancer Chemokine Chemokine Receptor
    Carci- CCL1, CCL4, CCL17, CCL19, CCL21, CCR7, CCR8,
    noma CCL22, CCL25 CCR9
    CXCL12, CXCL13, CXCL16 CXCR4, CXCR5,
    CXCR6, CX3CR1
    Leuke- CCL1, CCL4, CCL17, CCL19, CCL21, CCR7, CCR8,
    mia CCL22, CCL25 CCR9
    CXCL12 CXCR4
    Lym- CXCL12, CXCL13 CXCR4, CXCR5
    phoma
    Mela- CCL25, CCL27 CCR9, CCR10
    noma CXCL1, CXCL2, CXCL3, CXCL5, CXCR1, CXCR2,
    CXCL6, CXCL7, CXCL8, CXCL12, CXCR4, CXCR5,
    CXCL13, CXCL16 CXCR6
    CX3CL1 CX3CR1
    Sar- CCL1, CCL3, CCL4, CCL5, CCL7, CCR3, CCR5,
    coma CCL8, CCL11, CCL13, CCL17, CCR8
    CCL22, CCL24
    CXCL12 CXCR4
    CX3CL1 CX3CR1
  • Dosage would more commonly be in the range of 0.01 to 1000 mg/kg/da, more often in the range of 0.1 to 100 mg/kg/da. As expected, the dosage will be dependant on the condition, size, age and condition of the patient.

Claims (20)

1-14. (canceled)
15. A method of inhibiting carcinoma cell migration, comprising:
administering into said host a migration-inhibiting effective amount of a composition comprising:
(1) an anti-CCL25 antibody, a fragment of an anti-CCL25 antibody, an anti-CCR9 antibody, or a fragment of an anti-CCR9 antibody; and
(2) a pharmaceutically acceptable carrier,
wherein said composition is administered directly to tumor tissue.
16. The method of claim 15, wherein said anti-CCL25 antibody or said anti-CCR9 antibody is a human antibody.
17. The method of claim 15, wherein said anti-CCL25 antibody or said anti-CCR9 antibody is a humanized antibody.
18. The method of claim 15, wherein said anti-CCL25 antibody or said anti-CCR9 antibody is a chimeric antibody.
19. The method of claim 15, wherein said composition comprises both said anti-CCL25 antibody and said anti-CCR9 antibody.
20. The method of claim 15, wherein said pharmaceutically acceptable carrier comprises a solid support.
22. The method of claim 21, wherein said solid support is a sponge or gauze.
23. The method of claim 15, wherein said pharmaceutically acceptable carrier comprises liposomes.
24. The method of claim 15, wherein said pharmaceutically acceptable carrier comprises microspheres.
25. The method of claim 15, wherein said antibody is administered directly to tumor bed during an invasive procedure.
26. The method of claim 15, wherein said anti-CCL25 antibody, a fragment of an anti-CCL25 antibody, an anti-CCR9 antibody, or a fragment of an anti-CCR9 antibody is administered at a dose range of 0.01-1000 mg/kg/day.
27. The method of claim 15, wherein said anti-CCL25 antibody or said anti-CCR9 antibody is administered at a dose range of 0.1-100 mg/kg/day.
28. The method of claim 15, wherein said pharmaceutically acceptable carrier is saline.
29. The method of claim 28, wherein said saline is buffered saline.
30. The method of claim 15, wherein said pharmaceutically acceptable carrier is glucose in saline.
31. The method of claim 15, wherein said composition further comprises an antibody, or a fragment of an antibody, that binds to a chemokine or chemokine receptor selected from the group consisting of CCL1, CCL4, CCL17, CCL19, CCL21, CCL22, CXCL12, CXCL13, CXCL16, CCR7, CCR8, CXCR4, CXCR5, CXCR6, CX3CR1.
32. A method of inhibiting carcinoma cell growth in a host, comprising:
administering into said host a growth-inhibiting effective amount of a composition comprising:
(1) an anti-CCL25 antibody, a fragment of an anti-CCL13 antibody, an anti-CCR9 antibody, or a fragment of an anti-CCR9 antibody; and
(2) a pharmaceutically acceptable carrier.
33. The method of claim 32, wherein said composition comprises
(1) an anti-CCL25 antibody or a fragment of an anti-CCL25 antibody;
(2) an anti-CCR9 antibody or a fragment of an anti-CCR9 antibody; and
(3) a pharmaceutically acceptable carrier.
34. The method of claim 32, wherein said composition further comprises an antibody, or a fragment of an antibody, that binds to a chemokine or chemokine receptor selected from the group consisting of CCL1, CCL4, CCL17, CCL19, CCL21, CCL22, CXCL12, CXCL13, CXCL16, CCR7, CCR8, CXCR4, CXCR5, CXCR6, CX3CR1.
US12/967,816 2002-11-15 2010-12-14 Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms Abandoned US20110081407A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/967,816 US20110081407A1 (en) 2002-11-15 2010-12-14 Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42634702P 2002-11-15 2002-11-15
US10/712,398 US7919083B2 (en) 2002-11-15 2003-11-14 Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
US12/967,816 US20110081407A1 (en) 2002-11-15 2010-12-14 Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/712,398 Continuation US7919083B2 (en) 2002-11-15 2003-11-14 Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms

Publications (1)

Publication Number Publication Date
US20110081407A1 true US20110081407A1 (en) 2011-04-07

Family

ID=32326333

Family Applications (9)

Application Number Title Priority Date Filing Date
US10/712,398 Expired - Fee Related US7919083B2 (en) 2002-11-15 2003-11-14 Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
US12/967,816 Abandoned US20110081407A1 (en) 2002-11-15 2010-12-14 Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
US12/967,273 Expired - Fee Related US8097250B2 (en) 2002-11-15 2010-12-14 Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
US12/967,795 Abandoned US20110091528A1 (en) 2002-11-15 2010-12-14 Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
US12/968,659 Abandoned US20110081408A1 (en) 2002-11-15 2010-12-15 Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
US12/968,698 Abandoned US20110091529A1 (en) 2002-11-15 2010-12-15 Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
US13/014,310 Abandoned US20110150982A1 (en) 2002-11-15 2011-01-26 Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
US13/014,240 Abandoned US20110123603A1 (en) 2002-11-15 2011-01-26 Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
US13/886,559 Abandoned US20130243761A1 (en) 2002-11-15 2013-05-03 Methods for prevention and treatment of inflammation using anti-chemokine antibodies

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/712,398 Expired - Fee Related US7919083B2 (en) 2002-11-15 2003-11-14 Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms

Family Applications After (7)

Application Number Title Priority Date Filing Date
US12/967,273 Expired - Fee Related US8097250B2 (en) 2002-11-15 2010-12-14 Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
US12/967,795 Abandoned US20110091528A1 (en) 2002-11-15 2010-12-14 Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
US12/968,659 Abandoned US20110081408A1 (en) 2002-11-15 2010-12-15 Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
US12/968,698 Abandoned US20110091529A1 (en) 2002-11-15 2010-12-15 Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
US13/014,310 Abandoned US20110150982A1 (en) 2002-11-15 2011-01-26 Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
US13/014,240 Abandoned US20110123603A1 (en) 2002-11-15 2011-01-26 Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
US13/886,559 Abandoned US20130243761A1 (en) 2002-11-15 2013-05-03 Methods for prevention and treatment of inflammation using anti-chemokine antibodies

Country Status (3)

Country Link
US (9) US7919083B2 (en)
AU (1) AU2003291549A1 (en)
WO (1) WO2004045526A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10401357B2 (en) 2011-06-13 2019-09-03 Tla Targeted Immunotherapies Ab Treating cancer

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69841751D1 (en) * 1997-11-21 2010-08-12 Human Genome Sciences Inc Chemokin alpha-5
US20120135415A1 (en) * 2002-11-15 2012-05-31 Morehouse School Of Medicine Detecting cancer with anti-cxcl13 and anti-cxcr5 antibodies
US8512701B2 (en) * 2002-11-15 2013-08-20 Morehouse School Of Medicine Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration
US20120064089A1 (en) * 2002-11-15 2012-03-15 Morehouse School Of Medicine Anti-cxcl16 and anti-cxcr6 antibodies for the prevention and treatment of cancer and cancer cell migration
US9233120B2 (en) 2002-11-15 2016-01-12 Jyant Technologies Anti-CCL25 and anti-CCR9 antibodies for the prevention and treatment of cancer and cancer cell migration
US20050014165A1 (en) * 2003-07-18 2005-01-20 California Pacific Medical Center Biomarker panel for colorectal cancer
CA2501422C (en) * 2004-04-29 2014-08-12 University Of Rochester Lymphoid chemokines in the diagnosis, monitoring and treatment of autoimmune disease
US20100143899A1 (en) * 2005-05-17 2010-06-10 University Of Vermont And State Agricultural College Methods and products for diagnosing cancer
WO2007124414A2 (en) * 2006-04-21 2007-11-01 Centocor, Inc. Cxcl13 antagonists and their use for the treatment of inflammatory diseases
WO2008134020A1 (en) * 2007-04-26 2008-11-06 University Of Vermont And State Agricultural College Ccl18 and ccl3 methods and compositions for detecting and treating cancer
US20090028866A1 (en) * 2007-07-27 2009-01-29 John Wayne Cancer Institute USE OF CCR9, CCL25/TECK, AND NITEGRIN alpha4 IN DIAGNOSIS AND TREATMENT OF MELANOMA METASTASIS IN THE SMALL INTESTINE
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
US20120082659A1 (en) * 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
KR101051435B1 (en) * 2008-10-22 2011-07-22 한국생명공학연구원 Colorectal cancer diagnostic kit using colorectal cancer-related markers and colorectal cancer diagnostic method using the same
CA2742157A1 (en) * 2008-10-31 2010-05-06 Toray Industries, Inc. Immunoassay method for human cxcl1 protein
SI2356462T1 (en) * 2008-11-11 2017-05-31 The Regents Of The University Of Michigan Anti-cxcr1 compositions and methods
JP5801202B2 (en) * 2009-09-29 2015-10-28 学校法人慶應義塾 Antitumor agent and screening method thereof
WO2012031099A2 (en) 2010-09-02 2012-03-08 Vaccinex, Inc. Anti-cxcl13 antibodies and methods of using the same
US8435993B2 (en) 2010-12-07 2013-05-07 Philadelphia Health And Education Corporation Methods of inhibiting metastasis from cancer
JP2014505239A (en) * 2010-12-14 2014-02-27 モアハウス スクール オブ メディスン Use of anti-CXCL13 and anti-CXCR5 antibodies for the treatment or detection of cancer
EP2668508A2 (en) * 2011-01-27 2013-12-04 Virginia Commonwealth University Diagnostic and prognostic markers for metastasis
WO2012172341A2 (en) * 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Treating cancer
CN104520323B (en) 2012-03-02 2018-05-04 瓦西尼斯公司 Method for the inflammatory disease for treating B cell mediation
WO2013131010A2 (en) * 2012-03-02 2013-09-06 Icahn School Of Medicine At Mount Sinai Function of chemokine receptor ccr8 in melanoma metastasis
TWI467172B (en) * 2012-10-24 2015-01-01 Po Lin Kuo Method for selecting candidate for treating breast cancer metastasis
WO2014121053A1 (en) 2013-01-31 2014-08-07 Vaccinex, Inc. Methods for increasing immunoglobulin a levels
EP3416641A1 (en) 2016-02-16 2018-12-26 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Modulators of ccr9 for treating tumor resistance to immune responses
US20200164068A1 (en) 2016-02-16 2020-05-28 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Modulators of tumor immune resistance for the treatment of cancer
KR102531889B1 (en) 2016-06-20 2023-05-17 키맵 리미티드 Anti-PD-L1 and IL-2 cytokines
CA3046489A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018112264A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
WO2018204370A1 (en) 2017-05-02 2018-11-08 Drexel University Cx3cr1 small molecule antagonists, and methods using same
CN107964045B (en) * 2017-12-18 2021-04-23 南京医科大学 A human-mouse chimeric anti-CXCR2 whole molecule IgG and its application
EP3713957A4 (en) * 2018-09-18 2021-08-18 I-Mab Biopharma US Limited ANTI-CXCL13 ANTIBODY FOR TREATMENT OF AUTOIMMUNE DISEASES AND CANCER
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
EP3870261B1 (en) 2019-12-13 2024-01-31 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818542A (en) * 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO2000053635A1 (en) * 1999-03-11 2000-09-14 Millennium Pharmaceuticals, Inc. Anti-gpr-9-6 and anti-teck antibodies and methods of identifying modulators of gpr-9-6 and teck functions
WO2002024956A2 (en) * 2000-09-19 2002-03-28 Whitehead Institute For Biomedical Research Genetic markers for tumors
US20030165504A1 (en) * 1999-09-24 2003-09-04 Retter Marc W. Compositions and methods for the therapy and diagnosis of ovarian cancer
US20030235582A1 (en) * 2002-06-14 2003-12-25 Immunogen, Inc. Anti-IGF-I receptor antibody
US20040005563A1 (en) * 2001-06-18 2004-01-08 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20050065333A1 (en) * 2001-04-27 2005-03-24 Arun Seth Breast cancer-associated genes and uses thereof
US7361338B2 (en) * 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
US20110281814A1 (en) * 2009-01-30 2011-11-17 Genzyme Corporation Methods and compositions for treating breast cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723520B2 (en) * 1996-07-05 2004-04-20 Schering Corporation Antibodies that bind chemokine teck
US6110695A (en) * 1997-12-02 2000-08-29 The Regents Of The University Of California Modulating the interaction of the chemokine, B Lymphocyte Hemoattractant, and its Receptor, BLR1
WO1999050461A1 (en) 1998-03-30 1999-10-07 Northwest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis
US6863887B1 (en) * 1998-03-30 2005-03-08 Northwest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis
CN1441677A (en) * 2000-03-31 2003-09-10 Idec药物公司 Combined use of anti-cytokine antibodies or antagonists and anti-CD2O for treatment of B cell lymphoma
US20040029114A1 (en) * 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
US20040234979A1 (en) * 2001-03-30 2004-11-25 Zairen Sun Differentiall-expressed and up-regulated polynucleotides and polypeptides in breast cancer
EP1417488B1 (en) * 2001-06-07 2006-12-06 ChemoCentryx Inc Cell migration assay

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818542A (en) * 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO2000053635A1 (en) * 1999-03-11 2000-09-14 Millennium Pharmaceuticals, Inc. Anti-gpr-9-6 and anti-teck antibodies and methods of identifying modulators of gpr-9-6 and teck functions
US6936248B1 (en) * 1999-03-11 2005-08-30 Millennium Pharmaceuticals, Inc. Methods of inhibiting GPR-9-6 function
US20030165504A1 (en) * 1999-09-24 2003-09-04 Retter Marc W. Compositions and methods for the therapy and diagnosis of ovarian cancer
US7361338B2 (en) * 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
WO2002024956A2 (en) * 2000-09-19 2002-03-28 Whitehead Institute For Biomedical Research Genetic markers for tumors
US20050065333A1 (en) * 2001-04-27 2005-03-24 Arun Seth Breast cancer-associated genes and uses thereof
US20040005563A1 (en) * 2001-06-18 2004-01-08 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20030235582A1 (en) * 2002-06-14 2003-12-25 Immunogen, Inc. Anti-IGF-I receptor antibody
US20110281814A1 (en) * 2009-01-30 2011-11-17 Genzyme Corporation Methods and compositions for treating breast cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Koshiba et al, Clin Cancer Res, 2000;6:3530-3535 *
Scotton et al, Cancer Res, 2002, 62:5930-5938 *
Shen et al, J Gastointest Surg, 2009; 13:1955-1962 *
Wang et al, J Immunol Meth, 1998, 220:1-17 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10401357B2 (en) 2011-06-13 2019-09-03 Tla Targeted Immunotherapies Ab Treating cancer
US10408832B2 (en) * 2011-06-13 2019-09-10 Tla Targeted Immunotherapies Ab Treating mental disorders
US10422800B2 (en) 2011-06-13 2019-09-24 Tla Targeted Immunotherapies Ab Treating respiratory conditions
US10429385B2 (en) 2011-06-13 2019-10-01 Tla Targeted Immunotherapies Ab Treating conditions associated with sepsis
US10451620B2 (en) 2011-06-13 2019-10-22 Tla Targeted Immunotherapies Ab Treating conditions associated with metabolic syndrome
US10502736B2 (en) 2011-06-13 2019-12-10 Tla Targeted Immunotherapies Ab Treating multiple sclerosis

Also Published As

Publication number Publication date
US20110123603A1 (en) 2011-05-26
US20110091528A1 (en) 2011-04-21
US20110091529A1 (en) 2011-04-21
US8097250B2 (en) 2012-01-17
WO2004045526A3 (en) 2005-03-31
US7919083B2 (en) 2011-04-05
AU2003291549A8 (en) 2004-06-15
AU2003291549A1 (en) 2004-06-15
US20110081406A1 (en) 2011-04-07
US20110150982A1 (en) 2011-06-23
US20130243761A1 (en) 2013-09-19
US20040170628A1 (en) 2004-09-02
US20110081408A1 (en) 2011-04-07
WO2004045526A2 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
US8097250B2 (en) Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
US8580261B2 (en) Methods for prevention and treatment of inflammation using anti-chemokine antibodies
Browning et al. Lymphotoxin and an associated 33-kDa glycoprotein are expressed on the surface of an activated human T cell hybridoma.
Taylor Anti-TNF therapy for rheumatoid arthritis and other inflammatory diseases
WO2013174264A1 (en) Anti-blys antibody
Bui et al. Cytokine targeting in rheumatoid arthritis
JPWO2019228266A5 (en)
CN114044827B (en) Low ADCC/CDC functional monoclonal antibody and preparation method and application thereof
EP2866830A1 (en) Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation
CN110256583A (en) A kind of fusion protein and its application of IL-2 mutant and antibody
US20160130350A1 (en) Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation
Liu et al. Interleukin-6 in rheumatoid arthritis-from the laboratory to the bedside
EP2193790A1 (en) IL-3 Inhibitors in use for treatment of rheumatoid arthritis in an early stage
CN114555109A (en) Methods of treating cancer using IL-33 proteins
JPH05503098A (en) Cytokine antibodies for treatment of sepsis
JP4452839B2 (en) Pharmaceutical composition containing a CXCR3 inhibitor
TW202242142A (en) Blood gene expression biomarkers to predict response in patients with inflammatory bowel diseases
KR20220086522A (en) Use of TACI protein
CN113698484B (en) anti-IL-23R antibodies and uses thereof
CN111234021B (en) anti-CCR 5 antibody and application thereof in treating tumors
JP2024545101A (en) Methods of using inflammatory markers to guide anti-clever-1 cancer therapy
TW202332771A (en) Transgenic immune cell and construction method and application thereof
AU732764B2 (en) Rheumatoid arthritis remedy containing IL-6 antagonist as effective component
CN114773485A (en) Bifunctional fusion protein molecule of anti-human PD-L1 antibody and TGF beta RII
CN116848144A (en) anti-PD-L1 antibodies and uses thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: MOREHOUSE SCHOOL OF MEDICINE, GEORGIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LILLARD, JAMES W.;SINGH, SHAILESH;STILES, JONATHAN K.;REEL/FRAME:025533/0626

Effective date: 20101220

AS Assignment

Owner name: SINGH, SHAILESH, GEORGIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MOREHOUSE SCHOOL OF MEDICINE;REEL/FRAME:033346/0196

Effective date: 20130613

Owner name: STILES, JONATHAN K., GEORGIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MOREHOUSE SCHOOL OF MEDICINE;REEL/FRAME:033346/0196

Effective date: 20130613

Owner name: LILLARD, JAMES W., JR, GEORGIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MOREHOUSE SCHOOL OF MEDICINE;REEL/FRAME:033346/0196

Effective date: 20130613

Owner name: JYANT TECHNOLOGIES, GEORGIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LILLARD, JAMES W., JR;SINGH, SHAILESH;STILES, JONATHAN K.;REEL/FRAME:033346/0233

Effective date: 20140717

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载